Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes ...

Novartis announced new late-breaking data from the head-to-head CLEAR study, demonstrating that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Novartis announced that the China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric ...

"In this study, SKYRIZI showed superior efficacy compared to Cosentyx in helping patients achieve and maintain high levels of skin clearance at week 52," said Michael Severino, M.D., vice chairman and ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. DENVER (KDVR) — A Colorado board continues ...

MoonLake Immunotherapeutics (NASDAQ:MLTX), based in Switzerland, is a clinical stage developer of nanobody therapeutics for inflammatory diseases. Lead asset is sonelokimab, a tri-specific IL-17A & IL ...